Cargando…

Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients

The aims of this study were to evaluate the frequency of Achromobacter xylosoxidans infection in a cohort of cystic fibrosis patients, to investigate antimicrobial sensitivity, to establish possible clonal likeness among strains, and to address the clinical impact of this infection or colonization o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambiase, A., Catania, M. R., del Pezzo, M., Rossano, F., Terlizzi, V., Sepe, A., Raia, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132409/
https://www.ncbi.nlm.nih.gov/pubmed/21279730
http://dx.doi.org/10.1007/s10096-011-1182-5
_version_ 1782207818226466816
author Lambiase, A.
Catania, M. R.
del Pezzo, M.
Rossano, F.
Terlizzi, V.
Sepe, A.
Raia, V.
author_facet Lambiase, A.
Catania, M. R.
del Pezzo, M.
Rossano, F.
Terlizzi, V.
Sepe, A.
Raia, V.
author_sort Lambiase, A.
collection PubMed
description The aims of this study were to evaluate the frequency of Achromobacter xylosoxidans infection in a cohort of cystic fibrosis patients, to investigate antimicrobial sensitivity, to establish possible clonal likeness among strains, and to address the clinical impact of this infection or colonization on the general outcome of these patients. The study was undertaken between January 2004 and December 2008 on 300 patients receiving care at the Regional Cystic Fibrosis Center of the Naples University “Federico II”. Sputum samples were checked for bacterial identification. For DNA fingerprinting, pulsed-field gel electrophoresis (PFGE) was carried out. Fifty-three patients (17.6%) had at least one positive culture for A. xylosoxidans; of these, 6/53 (11.3%) patients were defined as chronically infected and all were co-colonized by Pseudomonas aeruginosa. Of the patients, 18.8% persistently carried multidrug-resistant isolates. Macrorestriction analysis showed the presence of seven major clusters. DNA fingerprinting also showed a genetic relationship among strains isolated from the same patients at different times. The results of DNA fingerprinting indicate evidence of bacterial clonal likeness among the enrolled infected patients. We found no significant differences in the forced expiratory volume in 1 s (FEV(1)) and body mass index (BMI) when comparing the case group of A. xylosoxidans chronically infected patients with the control group of P. aeruginosa chronically infected patients.
format Online
Article
Text
id pubmed-3132409
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31324092011-08-24 Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients Lambiase, A. Catania, M. R. del Pezzo, M. Rossano, F. Terlizzi, V. Sepe, A. Raia, V. Eur J Clin Microbiol Infect Dis Article The aims of this study were to evaluate the frequency of Achromobacter xylosoxidans infection in a cohort of cystic fibrosis patients, to investigate antimicrobial sensitivity, to establish possible clonal likeness among strains, and to address the clinical impact of this infection or colonization on the general outcome of these patients. The study was undertaken between January 2004 and December 2008 on 300 patients receiving care at the Regional Cystic Fibrosis Center of the Naples University “Federico II”. Sputum samples were checked for bacterial identification. For DNA fingerprinting, pulsed-field gel electrophoresis (PFGE) was carried out. Fifty-three patients (17.6%) had at least one positive culture for A. xylosoxidans; of these, 6/53 (11.3%) patients were defined as chronically infected and all were co-colonized by Pseudomonas aeruginosa. Of the patients, 18.8% persistently carried multidrug-resistant isolates. Macrorestriction analysis showed the presence of seven major clusters. DNA fingerprinting also showed a genetic relationship among strains isolated from the same patients at different times. The results of DNA fingerprinting indicate evidence of bacterial clonal likeness among the enrolled infected patients. We found no significant differences in the forced expiratory volume in 1 s (FEV(1)) and body mass index (BMI) when comparing the case group of A. xylosoxidans chronically infected patients with the control group of P. aeruginosa chronically infected patients. Springer-Verlag 2011-01-31 2011 /pmc/articles/PMC3132409/ /pubmed/21279730 http://dx.doi.org/10.1007/s10096-011-1182-5 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Lambiase, A.
Catania, M. R.
del Pezzo, M.
Rossano, F.
Terlizzi, V.
Sepe, A.
Raia, V.
Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
title Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
title_full Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
title_fullStr Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
title_full_unstemmed Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
title_short Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
title_sort achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132409/
https://www.ncbi.nlm.nih.gov/pubmed/21279730
http://dx.doi.org/10.1007/s10096-011-1182-5
work_keys_str_mv AT lambiasea achromobacterxylosoxidansrespiratorytractinfectionincysticfibrosispatients
AT cataniamr achromobacterxylosoxidansrespiratorytractinfectionincysticfibrosispatients
AT delpezzom achromobacterxylosoxidansrespiratorytractinfectionincysticfibrosispatients
AT rossanof achromobacterxylosoxidansrespiratorytractinfectionincysticfibrosispatients
AT terlizziv achromobacterxylosoxidansrespiratorytractinfectionincysticfibrosispatients
AT sepea achromobacterxylosoxidansrespiratorytractinfectionincysticfibrosispatients
AT raiav achromobacterxylosoxidansrespiratorytractinfectionincysticfibrosispatients